A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
We are looking to include two additional women who are early on in the postpartum period (under one year) and recovering from postpartum depression.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
This hotline will offer a range of support, including brief interventions, referrals to both community-based and telehealth providers as needed.
